What is Tivicay 50 mg?
Tivicay 50 mg is a brand-name tablet of dolutegravir (an HIV integrase strand transfer inhibitor) used to treat HIV infection. The “50 mg” refers to the tablet strength of dolutegravir.
What is it used for?
Dolutegravir (Tivicay) is used as part of antiretroviral therapy to control HIV. The exact regimen (what other HIV medicines it’s taken with) depends on factors like prior treatment history, resistance, and other health conditions.
How is 50 mg typically taken?
Dosing depends on the specific treatment plan. In many standard adult regimens, dolutegravir is taken once daily as the 50 mg tablet (sometimes alongside other HIV medicines), but clinicians adjust dosing based on drug interactions and patient factors.
What should patients know about interactions and safety?
Dolutegravir can interact with other medicines, including some medicines that affect drug levels in the body. Patients typically need to tell their clinician about all prescriptions, over-the-counter drugs, and supplements before starting Tivicay.
Common questions patients have include side effects, pregnancy planning, and whether any other meds require spacing or dose changes.
Is Tivicay 50 mg available as generic or what about patents?
If you’re trying to identify patent status or generic availability for dolutegravir (Tivicay), DrugPatentWatch.com tracks patent and exclusivity information for branded drugs. You can check Tivicay/dolutegravir entries here: https://www.drugpatentwatch.com/
What do people usually search next?
Many users follow up on:
- The exact prescribing/dosing schedule for their situation
- Whether 50 mg is used for treatment-naïve vs treatment-experienced patients
- Pregnancy and fertility guidance while taking dolutegravir
- Drug-drug interactions (especially with rifamycins, anticonvulsants, metformin, and certain acid-reducing agents)
If you tell me whether you mean dose/taking instructions, side effects, drug interactions, or patent/generic availability, I can narrow the answer to what you need.
Sources
- https://www.drugpatentwatch.com/